therivabio.com (TOVX): Rasio rega marang prakiraan pendapatan

TOVX (Theriva Biologics Inc) - tandha merek perusahaan

Theriva Biologics, Inc. (TOVX) is integrating AI models and automation into the development of immunotherapy, with business success relying on the efficacy of viral tumor treatments. A key milestone was the implementation of closed bioreactors to eliminate media contamination. The forward P/S multiple illustrates market expectations, with the metric currently at 21.20, determining the valuation of the company's future sales.

TOVX Theriva Biologics Inc: Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ing interval 08.05.2026 - 18.11.2026

Rincian analitis perusahaan Theriva Biologics, Inc. (TOVX)

Ringkesan analisis perusahaan:therivabio.com TOVX
Produk sing diprodhuksi Theriva Corp

Theriva Biologics, Inc. (TOVX) success in developing immunotherapeutic platforms to combat tumors in partnership with pharma behemoths determines the issuer's future cash flows. By analyzing the forward revenue multiple, an investor assesses the ratio of current market value to expected sales, which allows for an evaluation of the growth rates priced in and the degree of the stock's resilience to market volatility.

Analisis pesaing

ImmunityBio Inc - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Immunocore Corp IMCR|JANX - Rasio rega marang prakiraan pendapatan|RCUS (arcusbio.com) - Kapitalisasi marang prakiraan pendapatan|Zymeworks Biopharmaceuticals (ZYME) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Tango Pharma (TNGX)|Multiplikator forward rega marang pendapatan IOVA|IMTX - Prakiraan rega marang pendapatan|Multiplikator forward rega marang pendapatan XNCR (Xencor Corp)|Rasio rega marang pendapatan sing dikarepake CMPX|Multiplikator Forward P/S REPL (Replimune)|Rega forward marang dodolan LYEL|innate-pharma.com - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Pyxis Oncology|Compugen Limited (CGEN) - Rasio rega marang prakiraan pendapatan|IO Biotech, Inc. - Rega forward marang dodolan|STRO (sutrobio.com) - Multiplikator Forward P/S|Multiplikator Forward P/S MiNK Therapeutics Inc.|Rasio rega marang prakiraan pendapatan werewolftx.com (HOWL)|IMMX: Rega mangsa ngarep marang pendapatan|alxoncology.com - Multiplikator forward rega marang pendapatan|CUE - Multiplikator forward rega marang pendapatan|PDSB - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Sonnet BioTherapeutics Holdings SONN|MAIA: Multiplikator Forward P/S|LIMN - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan LVTX|Kapitalisasi marang prakiraan pendapatan NXTC (NextCure)|Rasio rega marang prakiraan pendapatan leaptx.com (LPTX)|INTS - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S SNSE (Sensei Biotherapeutics, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake gritstonebio.com (GRTS)|kinetabio.com - Multiplikator Forward P/S|NexImmune (NEXI) - Multiplikator forward rega marang pendapatan|turnstonebio.com (TSBX) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Vaccinex, Inc (VCNX)|Multiplikator forward rega marang pendapatan HARP